How closely related are allergic rhinitis (AR), asthma, and chronic rhinosinusitis (CRS)? Clinical experience has taught us that these three entities are, in fact, closely related. Evidence enumerating the existence of this relationship will be briefly explored here.
Immunologic evidence: AR is triggered primarily by an IgE-mediated immune response to environmental allergens. By activating numerous mediators and involvement of the cellular response, inflammation ultimately sets in at the tissue level. Upon initiation of this cascade, two phases of a type one allergic reaction occur, increasing the concentration of eosinophils, basophils, and neutrophils in nasal secretions and the epithelial lining of the nose, thus generating rhinorrhea and congestion.
The pathogenesis of asthma is very similar. A foreign invader such as a virus, allergen, or pollutant can trigger a cascade of immunologic events that results in tissue inflammation and edema. In the nose, this inflammatory response results in congestion, while in the bronchi these mediators cause airway narrowing and shortness of breath or wheezing.
In addition to the typical triggering factors in AR and asthma, CRS is further exacerbated by an association with bacterial and fungal insults. There is evidence that IgE antibodies also playa role in chronic sinusitis. Investigators have shown that total IgE levels correlate with the severity of sinusitis as assessed by computed tomography (CT) scan findings.' Staphylococcus aureus enterotoxins cause local increases in total IgE in over 50% of nasal polyp patients.' Elevations in total IgE have been shown to occur in patients with allergic fungal sinusitis, and subsequent total IgE levels have been shown to decrease with successful treatment.3.4 410 " www.entjournal.com Various triggers may have different presentations and thus create a clinically known diverse group of diseases that we have classically grouped as CRS. Once again, regardless of the nature of the trigger, inflammation is a common denominator in each of these entities' similar to AR and asthma.
At the tissue level, it is the final impact of humeral and cellular immunity that brings tissue changes and associated symptoms. The role of eosinophils, for instance, in CRS and polyposis is well documented. The prevalence of CRS in immune-deficient patients, allergic fungal sinusitis, Samters triad, and Churg-Strauss syndrome are further examples that demonstrate the integrated relation of the immune system and CRS. 3 In summary, these three diseases are linked by a similar inciting event that activates the immune system, leading to inflammation. The inflammatory response is predominantly Th2and IgE-mediated and involves eosinophils at the cellular level.' Atopy, therefore, is a major risk factor for the development of these diseases.
Epidemiologic evidence: AR occurs in about 85% of patients with asthma, and in 50 to 60% of patients with CRS, compared to the general population rate of 20%; in addition, asthma occurs in up to 40% of patients with AR, compared to the general population rate of about 10%.4.5 Abnormal sinus radiographs can be found in 40 to 60% of asthmatic patients, in which there is a direct correlation between the degree of radiographic findings and patient severity of asthma." Significant sinus disease on CT scan is associated with AR in 78% of patients and with asthma in 71% of patients." AR patients have a much higher propensity to develop asthma later in life compared to healthy con-
trols,"
Experimental evidence: Braunstahl demonstrated that stimulation of the nasal mucosa of sensitized allergic patients with an appropriate allergen resulted in increased bronchial symptoms compared to controls." This sensitization additionally resulted in infiltration of eosinophils of the bronchial mucosa.v" Interestingly, when bronchoscopy was used to introduce the allergen to the bronchial mucosa, an increase in nasal symptoms was also observed. Furthermore, an in-ENT-Ear, Nose & Throat Journal" September 2013 GUESTEDITORIAL crease in eosinophilic infiltration of the nasal mucosa was also observed.
In histologic studies, remodeling of the airway in asthma patients has been studied extensively. One of the features of this remodeling is thickening of the basement membrane. This same element has also been observed in the nasal mucosa of allergic patients without underlying asthma."
Clinical evidence: Treating patients who are afflicted with the aforementioned diseases while disregarding the possible coexistence of AR, asthma, or CRS is doomed to fail. Experienced clinicians will attest to the fact that when we focus on treating asthmatic pulmonary complaints while neglecting sinus and allergy conditions, lack ofsuccess in disease control and polypharmacy is typically the end result." Similarly, if we focus on allergic patients' nasal and sinus symptoms without regard to their asthma as a potential source of chronic cough, we do our patients a disservice. Finally, CRS will not respond to medical and surgical treatment if allergy and inflammatory disease are not adequately addressed, either prior to or in conjunction with other treatment modalities. Many clinicians consider AR, asthma, and CRS to be different manifestations of the same underlying condition.
Treatment evidence: Corticosteroids used in systemic or topical forms are effective treatment regimens for these three disorders. This is intuitive when we consider the fact that inflammation is the central theme for all three diseases. As further illustration, studies have shown that antibiotics used in the treatment of CRS may be more effective due to their anti-inflammatory effect rather than their antibacterial role."
Leukotrienes are known chemotactic agents for eosinophils. Therefore, it is logical to expect that leukotriene receptor inhibitors would have therapeutic effects in asthma, AR, and CRS with nasal polyposis. Studies have indeed exhibited therapeutic success regarding this group of medications in all three of these inflammatory diseases.":"
There is evidence that omalizumab may also improve symptoms of CRS, as well as AR and asthma. Clinical trials are under way in evaluating its role in the treatment of CRSY The beneficial crossover of various anti-inflammatory treatments is another attestation to the strong relationship that exists between these three disease entities.
